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Summary Bovine seminal ribonuclease (BSRNase) is an unusual member of the ribonuclease superfamily, because of its remarkable anti-
tumour and immunosuppressive properties. We describe here the construction, expression, purification and characterization of a panel of six
immunotoxins based upon this enzyme and show that we can increase its anti-tumour activity by over 2 x 104-fold. This is achieved by
improving tumour cell targeting using a single-chain Fv (scFv) directed against the oncofetal antigen placental alkaline phosphatase. As well
as the simple scFv-BSRNase fusion protein, we have constructed five other derivatives with additional peptides designed to improve folding
and intracellular trafficking and delivery. We find that the molecule most cytotoxic to antigen (PLAP)-positive cells in vitro is one that contains
a C-terminal 'KDEL' endoplasmic reticulum retention signal and a peptide sequence derived from diphtheria toxin. All these molecules are
produced in Escherichia cofi (E. coli) as insoluble inclusion bodies and require extensive in vitro processing to recover antigen binding and
ribonuclease activity. Despite incomplete ribonuclease activity and quaternary assembly, these molecules are promising reagents for specific
chemotherapy of cancer and are potentially less harmful and immunogenic than current immunotoxins.
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Toxin proteins from bacteria, fungi and plants have been well
studied in the development of cytotoxic conjugate or fusion
proteins under the broad term of 'immunotoxins'. Monoclonal
antibodies, their immunoreactive fragments, growth factors or
cytokines have been used as vehicles to direct these toxins to
tumour cells overexpressing the appropriate tumour-associated
antigen. Prime examples of these include Pseudomonas exotoxin
A, diphtheria toxin and ricin, which cause cell death by interfering
with essential components of the cell protein synthesis machinery
(for a review see Pastan et al, 1992). Whereas these immunotoxin
molecules have produced excellent results in vitro and in animal
studies, the very nature of these molecules have caused disap-
pointing results in the clinic (reviewed in Ghetie and Vitetta,
1994). These problems are due to the side-effects and immuno-
genicity ofthe immunotoxins.
Recombinant DNA technology has led to the rational design
and refinement of such immunotoxins to produce more potent,
less toxic, smaller, homogeneous molecules. For example,
Pseudomonas exotoxin A has been genetically altered to make
more effective immunotoxins: the N-terminal cell binding domain
has been replaced by alternative ligands (Chaudhary et al, 1989)
and the C-terminal REDLK sequence has been mutated to KDEL,
which is the consensus human endoplasmic retention sequence
(Brinkmann et al, 1991) and which improves cell trafficking.
Recombinantly produced fragments ofantibodies, selected against
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tumour-associated antigens are very often used in the construction
ofimmunotoxins to decrease their size and improve their pharma-
cokinetics, particularly as this technology has advanced so rapidly
with the arrival of antibody phage display (reviewed in Winter et
al, 1994). Single-chain Fv fragments (scFvs, reviewed in Huston et
al, 1993) ordisulphide-linked Fv fragments (dsFvs) are commonly
used to target toxins to target cells (Brinkmann et al, 1991, 1993).
However, despite the use of human antibody fragments and
small toxins, there is the risk of an immune response against the
non-human toxin, thereby reducing its effectiveness as a result of
rapid clearance of subsequent doses and adverse side-effects. A
novel advance in this field was the use ofenzymes ofmammalian
or human origin in place of the toxin. It was shown that a
mammalian enzyme, bovine pancreatic ribonuclease (RNAase A)
could be as cytotoxic as ricin when micro-injected directly into
Xenopus oocytes (Rybak et al, 1991). This observation led to
the construction of immunotoxins based upon transferrin or anti-
transferrin receptor antibodies linked to RNAase A (Newton et al,
1992) and to human ribonucleases from the same family: angio-
genin (Rybak et al, 1992) and EDN (eosinophil-derived neuro-
toxin) (Newton et al, 1994). However, even before this work, it
was known that bovine seminal ribonuclease (BSRNase) had
inherent anti-tumour properties, without any obvious cell-
targeting moiety (Vescia et al, 1980). Another anti-tumour ribo-
nuclease, onconase, isolated from bull frogs is believed to be
similar to BSRNase and is currently under intense study as an
anti-tumour drug in combination with other cancer treatment
modalities (Rybak et al, 1996).
Bovine seminal ribonuclease is a member of the ribonuclease
superfamily, which includes RNAase A, angiogenin and EDN.
*Present address: Antisoma, West Africa House, Hanger Lane, Ealing, London
W5 3QR, UK
537538 MP Deonarain andAA Epenetos
These enzymes are all small, compact proteins with a molecular
weight of about 13 kDa. BSRNase is the only dimeric member of
this family (molecular weight 26 kDa) by virtue of two intersub-
unit disulphide bridges. It has a number of unusual properties
related to its ribonuclease activity and dimeric structure (reviewed
in D'Alessio et al, 1992; Kim et al, 1995a and b). These include
anti-tumour cell activity, which is more pronounced on metastatic-
derived cells. This phenomenon has been demonstrated in vitro
and in vivo (Laccetti et al, 1992, 1994). In addition, it has
immunosuppressive activity (Matousek et al, 1995), degrades
double-stranded RNA and demonstrates allosteric regulation
(D'Alessio et al, 1992). The dimeric structure, mammalian origin
and immunosuppressive nature of this protein makes it an attrac-
tive candidate for an immunotoxin. It is anticipated that, although
this protein is of bovine origin, it will be very well tolerated in
humans, as the homologous RNAase A has been used clinically to
treat tick-borne viral encephalitis (Glukhov et al, 1976) and
chronic myelocytic leukaemia (Alekandrowicz, 1958), with no
adverse or immunogenic reactions. The ribonuclease and cell-
targeting activities of bovine seminal RNAase and onconase are
being tested in anti-viral experiments to treat human immuno-
deficiency virus infections (Youle et al, 1994).
We describe here the construction, bacterial expression, purifica-
tion and characterization of a number of scFv-BSRNase immuno-
toxins. The scFv is directed against the tumour-associated antigen
human placental-like alkaline phosphatase (PLAP), which is an
isoform of the placental alkaline phosphatase. This antigen is
expressed on many tumours, such as ovarian and testicular, as well
as some bladder and head and neck cancers (Epenetos et al, 1984;
Iles et al, 1994). The antibody used is the well-studied H17E2
(Travers and Bodmer, 1984; Epenetos et al, 1986). The single-chain
Fv has been constructed (Savage et al, 1993) and characterized in
detail in vitro and in vivo (Deonarain et al, 1997). We have previ-
ously shown that this recombinant antibody localizes to tumours
more rapidly than the IgG form in a mouse xenograft model of
human cancer (Deonarain et al, 1997); it can be used to target
interleukin 2 to tumour cells (Boleti et al, 1986) and diagnostically
in immunohistochemical staining for PLAP-positive tumours
(Spooner et al, 1994).
The immunotoxins described in this report differ by the addition
of sequences designed to improve activity and potentiate the
cytotoxicity of the molecule, based upon previous work; the addi-
tion of a disulphide-bond-forming loop from diphtheria toxin can
greatly increase immunotoxin cytotoxicity (O'Hare et al, 1990)
and a 'KDEL' endoplasmic reticulum retention signal can increase
ricin immunotoxin cytotoxicity by ten- to 250-fold (Wales et al,
1993). In addition, it has been shown that peptides linking
chimaeric molecules can modulate the activity of the molecule
(Brinkmann et al, 1992). We envisage that tumour targeting of
fusions of mammalian enzymes such as these could potentially
improve upon conventional immunotoxins, because of their
increased cytotoxicity when targeted to the correct cellular
compartments, the absence of any side-effects and their expected
lower or complete lack of immunogenicity in clinical use
(Deonarain and Epenetos, 1994).
MATERIALS AND METHODS
Materials
Cell lines H.Ep-2, a human larynx epidermal carcinoma (Toolan,
1954), A431, a human eperdermoid carcinoma and all cell culture
media were supplied by the cell culture services of the Imperial
Cancer Research Fund (London, UK). Cell line KB, a human oral
epidermal carcinoma (Eagle, 1955), was a gift from Dr Ray Iles
(St Bartholomew's Hospital, London, UK). The antibody H17E2
(Travers and Bodmer, 1984) was supplied by the hybridoma unit
of the Imperial Cancer Research Fund. The anti-mucin antibody
ASM2 was supplied by Dr Nigel Courtenay-Luck (Antisoma).
Polyclonal antibodies against the native and denatured form of
bovine seminal ribonuclease for detection in ELISAs and western
blotting were prepared as described in Deonarain and Epenetos
(1995). The H17E2 scFv plasmidconstructs andproteins have been
described previously (Deonarain et al, 1997). Pure native seminal
ribonuclease was a gift from Professor K Scheit (Max-Plank
Institute, Heidelberg, Germany).
Construction of the different scFv-BSRNase fusion
protein genes
All recombinant techniques used were essentially as described in
Sambrook et al (1989). The plasmid pBSV5, containing the gene
for the secreted form of the bovine seminal ribonuclease enzyme,
was kindly provided by Professor K Scheit (Preuss et al, 1990). A
XhoIlEcoRI cassette containing the gene for the processed form of
the enzyme was obtained by polymerase chain reaction (PCR)
amplification with the following conditions: 30 cycles of 94°C
(1 min), 72°C (1 min), 65°C (1 min) preceded by a 'hot start'
and followed by 3 min at 72°C from this plasmid using the
primers BSRNXHO 5'-GTGCGGGTCCTCGAGATCAAGCG-
CAAGGAATCTGCAGCTGCC-3' and BSRCECO 5'-GAAGC-
GGTGGAATTCACTGTTCTGGCCTCAGGT-3'. The gene forthe
BSRNase was fused to the C-terminus of the kappa light-chain
variable region of the insolubly expressed H17E2 scFv gene in
plasmid pSPH17E2 (Deonarain et al, 1997) to form the plasmid
pSPH17-BSR. An N-terminal linker/spacer (Ala-Pro-Ala-Ala-Ser-
Pro-Ala-Asp-Ala), to separate the scFv from the BSRNase,
was incorporated by amplifying the BSRNase gene with the
N-terminal primer BSRLINK 5'-GTGCGGGTCCTCGAGAT-
CAAGGCACCTGCTGCCTCCCCGGCAGACGCTAA GGATC-
TGCAGCTGCC-3' and the C-terminal primer BSRCECO. A
C-terminal Lys-Asp-Glu-Leu sequence (KDEL) was attached by
amplifying the BSRNase gene with the C-terminal primer
BSRKDEL 5'-CTGGGCGTGGAATTCTTATTACAGTTCGTC-
CTTCACTGAAGCATCGAA-3' and the N-terminal primer
BSRNXHO. A 22-amino-acid sequence containing the diphtheria
toxin disulphide loop (O'Hare et al, 1990) was inserted
between the scFv and BSRNase as a XhoVISalI cassette obtained
by PCR amplification from clone pRAS50 (R Spooner,
unpublished results) using the primers DTLOOPFW
5'-GGCTGACGTCTCGAGATCAAGCGCTCTAGCCTC-
GAAGGTGGGTGCGCTGGTAATAG-3' and DTLOOPBK
5'-AATTCGGACGTCGACGTCGAGACCACCGCAAGACA-
GGC-3'. Six constructs were made in total, with different permuta-
tions of N-terminal linker, C-terminal KDEL and diphtheria toxin
disulphide loop. In order to facilitate purification ofthese proteins,
six more plasmid constructs were made in which a hexahistidine
affinity peptide was placed at the N-terminus, thus allowing
isolation by immobilized metal affinity chromatography. The
N-terminus was chosen to avoid interfering with the C-terminal
'KDEL' sequences (see below). The pel B leader sequence was
also removed at this stage as it was not required (the proteins
were not secreted solubly, see below). These alterations were
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Figure 1 (A) Construction of the various scFv H17-bovine seminal ribonuclease fusion genes. The parental scFv-expressing plasmid is pSPH17 (Deonarain
et al, 1997) and all fusion constructs are derived from this. Each BSRNase cassette was obtained by PCR amplification of the gene from the plasmid pBSV5
(Preuss et al, 1990) using the oligonucleotides described in the text. Six plasmid constructs were made in total, each with a prefix pSP followed by 'H17' for the
scFv H17E2, 'BSR' for bovine seminal ribonuclease, 'K' for the C-terminal KDEL, 'L' for the N-terminal linker and 'DT' for the diphtheria toxin disulphide loop.
The N-terminal domain of the scFv was replaced at a later stage to incorporate a His6 affinity purification tag and to remove the pelB leader sequence on all six
original constructs to give the final constructs illustrated. (B) Schematic diagram illustrating the intended modular domain structure of the constructed
immunotoxins, with different permutations of the additional sequences
carried out in a single PCR reaction using primers
H17HISTAG 5'-TCAGAAGCTTGCATGCAAATTCTATTTC-
AAGGAGACAGTCATAATGAAACACCACCATCAC-
CACCATGCCCAGCTGCAGGAG-3' and H17SAC I 5'-GGCTG-
GAGACTGGGTGAGCTCGAT to create a new N-terminal
HindIII/SacI cassette, which replaced the original fragment in each
ofthe fusion protein constructs (Figure IA).
All of the constructs were sequenced by dideoxy sequencing to
ensure that no spurious alterations had arisen. The construction of
these clones is illustrated in Figure IA and for clarity the predicted
structures and modular assemblies ofthe fusion proteins are shown
schematically in Figure lB.
Expression of recombinant protein
E. coli BL21(XDE3) cells (Studier and Moffat, 1986) were trans-
formed by the plasmids for the scFv (Deonarain et al, 1997)
and fusion proteins. Single colonies were picked, re-streaked
and grown overnight at 37°C in L-Broth supplemented with
100 gg ml' ampicillin. These starter cultures were used to inocu-
late 500-ml cultures and were grown to an A6M of 1.0. At this
point, IPTG was added to 0.5 mm and induction of recombinant
protein was allowed for 3-6 h at 37°C. Cell pellets were harvested
by centrifugation and stored at -70°C until required.
Refolding and purification of recombinant protein
The expressed proteins accumulated as cytoplasmic inclusion
bodies, which were recovered from the insoluble cell components
as described by Buchner et al (1992) with slight modification:
spheroplasts were prepared from the cell pellets by osmotic shock
in 20% sucrose. The spheroplasts were resuspended (40 ml 1-' of
cell culture) in buffer A (50 mm Tris-HCl, 20 mm EDTA, pH 8.0),
lysozyme was added to 200 tg ml-1, and the suspension was mixed
by inversion for 2-16 h at 40C. The suspension was then sonicated
on ice, Triton X-100 was added to 2% and sodium chloride was
added to 0.5 M. This mixture was left to incubate at room tempera-
ture for 30 min. The lysate was centrifuged at 25 000 r.p.m. in a
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Beckman 45Ti rotor at 10°C for 30 min. The insoluble material
was resuspended in 40 ml of buffer A, sonicated on ice and
centrifuged as above. This process was repeated a total of four
times until semi-pure, washed inclusion bodies were isolated. The
final centrifugation step was used to aliquot the samples in batches
for storage at -70°C. Initial attempts to obtain pure protein were
unsuccessful until hexahistidine affinity tags were re-engineered
onto all ofthe clones. These inclusion bodies were further purified
as follows: the insoluble pellet was dissolved (10 ml l-1 oforiginal
culture) in 6 M guanidine hydrogen chloride (GuHCl), 50 mM Tris-
HCl, 5 mm magnesium chloride, pH 8.0, for 2-16 h. Undissolved
material was removed by ultracentrifugation at 30 000 r.p.m. for
30 min at 15°C. The clarified, denatured inclusion body prepara-
tion was applied to a 5-ml chelating sepharose (Fast-flow,
Pharmacia) column, charged with copper (II) ions and equilibrated
in buffer B (8 M urea, 50 mm Tris-HCl, pH 8.0). The protein was
allowed to bind by gentle inversion for 2-16 h at4°C. The column
was then packed down, washed and eluted as follows: 50 ml of
buffer B, 50 ml each of 10 mm, 20 mM, 40 mm and 150 mM imida-
zole dissolved in buffer B. The column was finally stripped by
washing with 50 ml of 50 mM EDTA, 0.5 M sodium chloride. The
majority of pure scFv-BSRNase protein eluted at 150 mM imida-
zole. The pure fractions (as judged by SDS-PAGE) were pooled,
concentrated to about 5 mg ml' in a volume of 2-5 ml and
reduced by the addition ofdithioerythritol to a final concentration
of0.3 M for 1 h. This process yielded pure, reduced and denatured
fusion protein.
Refolding was carried out by rapid dilution of the reduced and
denatured protein, 1:100 in a refolding buffer containing 0.5 M L-
arginine, 100 mM Tris-HCl, 2 mM EDTA and 4 mM oxidized
glutathione (GSSG), pH 8.0. This was carried out at 10'C and the
samples were incubated at 10°C for 48-72 h. Refolded samples
(0.5-1.0 1) were dialysed against 20 mm Tris-HCl, pH 8.0 (two
changes of 5-10 1 each), concentrated 50-fold by ultrafiltration in
an Amicon 8400 stirrer cell with a PM30 membrane and dialysed
exhaustively against 20 mM Tris-HCl, pH 8.0. In order to promote
the formation of disulphide-linked dimers, the refolded samples
were reduced by the addition of DTT to 2 mm and incubated for
1 h. These samples were then dialysed as before to remove excess
DTT and glutathione. Samples were dialysed into phosphate-
buffered saline (PBS) for cell binding and cytotoxicity studies or
stored frozen until required.
Analytical and preparative gel filtration
Analyses of the native molecular weights and quaternary struc-
tures of the fusion proteins were carried out by gel filtration on a
Superose-6 column (Pharmacia), equilibrated in 20 mM Tris-HCl,
pH 8.0, 0.1 M sodium chloride. Samples eluting at volumes corre-
sponding to monomers (45 kDa) and dimers (90 kDa) were
collected and characterized.
Ribonuclease assays
Qualitative RNA-degrading assays were carried out by incubating
5 jig of yeast RNA with the sample and analysing on an agarose
gel, as described before (Deonarain and Epenetos, 1995).
Quantitative assays were performed by spectrophotometrically
following the decrease in A300 of the RNA in a 1-cm pathlength
cuvette containing 1 mg ml-' yeast RNA, 0.1 M Tris-HCl, 0.15 M
sodium chloride, pH 7.5, at room temperature (based on an assay
described in Kunitz (1946)). These measurements were made with
reference to standard blank and native seminal RNAase-
containing samples.
Cytoxicity assays
The refolded proteins were dialysed against PBS and tested forcell-
killing activity on antigen-positive cell lines KB and H.Ep-2 and on
the antigen-negative cell line A431. In each assay, I04 cells were
grown in a 96-well microtitre plate in a volume of 100 jul of media
(2% RPMI 1640/10% fetal calf serum). Then, 20 jl, appropriately
diluted in PBS and 0.2-jim filtered, ofrefolded fusion protein were
added to each well in triplicate. The samples were incubated at
37°C/5% carbon dioxide for 72 h. Cell viability was determined by
measuring the level ofprotein synthesis in a [3H] Leucine incorpo-
ration assay. In this assay, 1 jCi of [3H] Leu was added per well and
incubated for 4 h at 37°C/5% carbon dioxide. The cells were
harvested with LKB betaplate harvester and the cellular incorpo-
rated radioactivity was counted. Control samples used were PBS,
native seminal ribonuclease, whole IgG and scFv H17E2. For
competition conditions, the above assay was carried out in the
presence of 10 jig ml' (67 nM) H17E2 IgG and ASM2 IgG.
Enzyme-linked immunosorbent assays and Western
blots
ELISAs were carried out in 96-well microtitre plates coated in
20 jig ml' hPLAP in PBS or 105 cells per well KB orH.Ep-2 cells,
fixed with 0.25% gluteraldehyde (as described in Deonarain and
Epenetos, 1995). The bound samples were detected using rabbit
anti-sera against pure native seminal ribonuclease followed by
donkey anti-rabbit horseradish peroxidase diluted in PBST (PBS
with 0.05% Tween-20).
ForWestern blot analysis, proteins were separated by 15% SDS-
PAGE under reducing conditions as described in Deonarain and
Epenetos (1995) and transferred onto nitrocellulose using a Biorad
semi-dry blotting apparatus, under the manufacturer's conditions.
The membranes were blocked with 5% non-fat milk protein in
PBST and proteins detected as described for ELISA using poly-
clonal antibodies against the denatured form ofthe enzyme.
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Figure 2 Expression (left panel) of all six scFv Hi7E2-BSRNase fusion
proteins in E. colistrain BL21 (XDE3) and their purification (right panel). Lane
1, scFv H17E2; lane 2, H17-BSR; lane 3, H17-BSR-K; lane 4, H17-L-BSR-K;
lane 5, H17-DT-BSR; lane 6, H17-DT-BSR-K; lane 7, H17-DT-L-BSR-K; M,
molecular weight markers. Proteins were analysed on a 10% reducing and
denaturing polyacrylamide gel stained with Comassie Brilliant Blue R-250
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RESULTS
Construction and expression of the scFv-BSRNase
fusion proteins
The initial scFv-BSRNase fusion protein construct consisted of a
straightforward linkage of the C-terminus of the scFv V K region
to the native BSRNase N-terminus. This site was chosen as
examination of the three-dimensional structure indicated that
the C-terminus was less accessible (Capasso et al, 1983). The
amplification oligonucleotides were designed to produce a
BSRNase cassette with an N-terminal XhoI site followed by a Ile-
Lys-Arg sequence to replace the same sequence found at the end
of the scFv (Figure IA). Further constructs were made with a
C-terminal 'Lys-Asp-Glu-Leu' sequence (KDEL), which was
introduced by PCR amplification. Another strategy designed to
improve the immunotoxin potency was the addition of a peptide
sequence from diphtheria toxin, which was predicted to form a
disulphide-containing loop. It was hoped that the addition of this
sequence would allow the release of the ribonuclease portion of
the immunotoxin from the antigen-bound scFv, once inside the
reducing environment ofthe cytosol. The final modification ofthe
scFv-BSRNase fusion protein constructs was the inclusion of a
spacer/linker sequence between the scFv and the BSRNase. This
was added to separate further the two portions of the molecule to
allow better independent folding (as observed for Pseudomonas
exotoxin immunotoxins; Brinkmann et al, 1992). In addition, it
has been shown that the N-termini of the BSRNase dimer are
exchanged across the subunit interface in some forms ofthe dimer
(Cafaro et al, 1995). Thus, a flexible linker between the two
moieties may reduce steric hindrance that may interfere with this
exchange process.
Initially, the expressed fusion proteins were found to be mostly
cytoplasmic inclusion bodies with a little insoluble periplasmic
material, despite the inclusion of a pel B leader sequence. This
was not surprising, as the parental scFv is expressed insolubly
(Deonarain et al, 1997) and many bacterially expressed ribonucle-
ases are insoluble. Expression levels were high, with about 10% of
the total cellular protein being recombinant protein. The expressed
proteins were analysed by SDS-PAGE under reducing conditions
and found to have approximately the expected molecular weight.
Initial experiments indicated that thepel B leader sequence was
not required, therefore a second set of constructs was made to
incorporate a His6 affinity purification tag at the N-terminus, in
place of the leader. This was done so as not to interfere with the
C-termini of the ribonuclease enzyme, some of which possessed
the KDEL sequence. This latter sequence must be at the extreme
C-terminus to function effectively. These new constructs were made
by replacing the same HindlIL/SacI cassette with a PCR-mutated
version containing the alterations (Figure IA). Their expression in
E. coli BL21 (XDE3) was similar to that ofthe unaltered forms and
they were of, approximately, the expected molecular weight
(Figure 2, left panel).
Purification and refolding of the recombinant proteins
Attempts to purify the initially constructed scFv-BSRNase fusion
proteins (without His6 tags) were unsuccessful, as immobilized
placental alkaline phosphatase was not stable under the purifica-
tion conditions tested. In contrast, immobilized metal ion affinity
chromatography of the His6-containing proteins under denaturing
conditions yielded essentially pure protein for all six constructs
(Figure 2, right panel). Each protein had approximately the correct
predicted molecular weight and were the correct relative size
(predicted weight in daltons): H17-BSR, 45 024; H17-BSR-K,
45 450; H17-L-BSR-K, 46 223; H17-DT-BSR, 46 444; H17-DT-
BSR-K, 46 800; H17-DT-L-BSR-K, 47 222.
Many methods, which have already been described, have been
tested for refolding the initial scFv-BSRNase fusion protein
(Deonarain and Epenetos, 1995). Each of these methods varied in
their efficiency to completely regenerate active chimaeric mole-
cules. The method eventually used was based on thatofBuchneret
al (1992), which gave good antigen-binding activity as well as
reasonable but not complete ribonuclease activity (see below), and
was chosen as an acceptable compromise.
Molecular weights of the fusion proteins
Gel filtration chromatography analyses of freshly refolded H17-
BSR fusion protein showed that there was a mixture (approxi-
mately 1:2) of monomeric (45 kDa) and aggregated (>250 kDa)
proteins, indicating that the refolding method was not effective in
regenerating dimers of seminal ribonuclease (Figure 3, upper
panel). We hypothesized that the intersubunit disulphide bonds
were blocked by the glutathione used in the refolding mixture, thus
preventing association of the protomers. Reduction with DTT
followed by exhaustive dialysis seemed to confirm this, as a
proportion of the fusion protein was formed into species with a
A D M
Column elution volume
Figure 3 Gel filtration traces of the purified fusion proteins after refolding,
before (upper figure) and after (lower figure) reduction/dialysis treatment to
promote dimer formation. A indicates the position of higher-molecular-weight
aggregates, D indicates the expected position of dimers and M indicates the
expected position of monomers
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Table 1 Equilibrium dissociation constants for the various preparations of the scFv-BSRNase fusion proteins and control samples
Protein KD (nM)
Unresolved mixture Monomeric fraction Dimeric fraction
Refolded scFv (H17E2) NA 36 ± 5 NA
H17-BSR 23±3 60±7 5±0.9
H17-BSR-K 21 + 3 62 ±8 NT
H17-L-BSR-K 17 ± 2.5 59 ± 7 NT
H17-DT-BSR 19 ± 2 48± 4.5 NT
H17-DT-BSR-K 22 ± 4 42 ± 5 NT
H17-DT-L-BSR-KL 17 ± 3 48 ± 4 NT
H17E2 IgG NA NA 0.2 0.04
These results are the mean of triplicate experiments with standard errors included. NA, not applicable. NT, not tested.
Table 2 Ribonuclease activities of purified bovine seminal ribonuclease and
scFv-BSRNase samples
Protein RNAase activity
LA3M x 103 S-1 mg-1 protein
Refolded scFv (H17E2) 0
H17-BSR 0.3 ± 0.04
H17-BSR-K 0.26 ± 0.05
H17-L-BSR-K 0.3 ± 0.034
H17-DT-BSR 0.29 ± 0.03
H17-DT-BSRe-K 0.24 ± 0.029
H17-DT-L-BSR-K 0.21 ± 0.026
Native BSRNase 5.2 ± 0.6
The assay was based upon the method described by Kunitz (1946). These
results are the mean of triplicate experiments with standard errors included.
molecular weight corresponding to dimers after this treatment
(Figure 3, lower panel). However, not all the protein 'dimerized',
suggesting that there were other constraints and that other factors
needed to be considered. Using gel filtration chromatography, we
were able to isolate enough monomeric scFv-BSRNase fusion
protein from the mixture forfurther characterization. Also, a small
amount ofwhat we would tentatively call 'dimeric fusion protein'
(from the H17-BSR sample) was isolated and analysed by ELISA
(Table 1). The binding affinity for this protein was higher than that
of the monomeric fusion proteins, but still about 25-fold lower
than the dimeric IgG. Non-reducing SDS-PAGE analysis of this
sample showed that the fusion protein migrated with a molecular
weight of about 45 kDa, with some higher-molecular-weight
species, whereas the monomer migrated at 45 kDa (data not
shown). However, interpretation of this data was difficult because
ofthe abnormal migration ofthese non-reduced proteins as a result
of the high number of disulphide bonds present. Overall, the
results suggest that there is a mixture ofcovalent and non-covalent
dimers, but we were unsuccessful in generating appreciable
amounts of pure dimer. The observations with this sample were
similar in the cases of the other five fusion proteins (data not
shown).
Activities of the refolded scFv-BSRNase molecules
The refolded ribonuclease fusion molecules demonstrated the
ability to bind pure or cellular PLAP in ELISAs. Equilibrium
binding constants were derived from ELISA analyses on pure
PLAP for all six constructs (afterrefolding and monomerisolation)
and the 'dimeric' form of the scFv-BSRNase fusion protein was
isolated by gel filtration chromatography (Table 1). These compar-
ative ELISAs gave an approximate value for the functional affini-
ties of the proteins and showed that the unresolved mixture of
fusion proteins had a consistently higher binding affinity than the
parental scFv. As expected the monomeric fusion proteins had
affinities similar to that of the scFv, which suggests that the
refolding of the scFv portion of the chimaeric molecule was
efficient. However, the dimeric form did not have an affinity
approaching that of the dimeric H17E2 IgG. Therefore, there is
physical and functional evidence that dimers are present after
refolding but, because of folding complexities, the majority of the
protein is aggregated with about one-third ofresolvable monomers.
The measured specific RNA-degrading activities of all the
fusion proteins were high, but still less than that of native
BSRNase. The activities ranged from about 10% to 20% of the
predicted activity, taking into account the increase in molecular
weight (Table 2). This is probably as a result ofthe complex nature
of the refolding of these molecules and the high number of disul-
phide bridges to be formed (14 per dimer), resulting in non-
optimal and incomplete refolding ofthe ribonuclease moiety.
Cytotoxicity of the scFv-BSRNase molecules
The purified, refolded monomeric scFv H17-BSRNase molecules
were tested for cell-directed toxicity on antigen-positive cells (KB
or H.Ep-2). Up until this point, all the generated molecules had
behaved similarly in terms of antigen binding and ribonuclease
activity. H17E2 in scFv or IgG form was not toxic to these cells at
concentrations of up to 50 ,UM (Figure 4A and Table 3). Native
bovine seminal ribonuclease was mildly toxic to these cells with
an IC50 of about 100 ,ug ml-} (3.6giM). These findings are similar
to those published by Laccetti et al (1992) (50 jg ml'), demon-
strating that BSRNase has an inherent anti-tumour activity to
epithelially derived tumour cell lines - more specifically, those
derived from metastases. All the cell lines that we tested were of
epithelial, metastatic origin. Native BSRNase was also seen to be
cytotoxic to a PLAP-negative tumour cell line with similar
potency (Table 3).
The scFv-targeted BSRNases were all much more toxic than
non-targeted BSRNase. The proteins were more toxic to the KB
cell line (Figure 4A and Table 3) than the H.Ep-2 cell line (Table 3),
probably because the KB cell line expresses a higher number of
PLAP receptors on the cell surface (Deonarain et al, 1997). The
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Table 3 Cytotoxicity measurements of the purified monomeric scFv-BSRNase fusion proteins on PLAP-positive (KB and H.Ep-2) and PLAP-negative (A431)
cell lines
Protein KB cells H.Ep-2 cells A431 cells
(PLAP positive) (PLAP negative) (PLAP negative)
IC50 (nM) lC, (nM) ICso (nM)
H17-BSR 4.2 ± 0.7 35 ± 4.7 > 105
H17-BSR-K 1.3 ± 0.1 11 ± 1.3 > 105
H17-L-BSR-K 1.1 ± 0.15 10± 1.8 > 105
H17-DT-BSR 3.3 ± 0.45 27 ± 3.2 > 105
H17-DT-BSR-K 0.43 ± 0.06 3.9 ± 0.5 > 105
H17-DT-L-BSR-K 0.31 ± 0.04 2.4 ± 0.35 > 105
H17E2 IgG > 105 > 105 > 105
H17E2 scFv > 105 > 105 > 105
Native BSRNase 3650 3675 3675
The maximum concentration of protein that could be achieved for certain experiments was 105 nm (about 5 mg ml-' for the scFv and scFv-BSRNase and
15 mg ml-' for the IgGs). These results are from three separate cell-killing experiments. Standard errors have been included when appropriate.
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Figure 4 (A) Cytotoxicity assay of the refolded monomeric scFv H17-BSRNase fusion proteins and control samples against KB cells tested in vitro. Toxicity
was measured by the inhibition of protein synthesis determined by a [3H]Leucine incorporation assay. Samples were incubated for 72 h as described in the text.
All measurements are relative to a control incubation in which PBS was incubated with the cells. The samples are as follows: H17-BSR (-0-), H17-BSR-K
(-+-), H17-L-BSR-K (-L-), H17-DT-BSR (-A-), H17-DT-BSR-K (-U-), H17-DT-L-BSR-K (-A-), native BSRNase (-4-), H17E2 IgG (-x-) and H17E2 scFv
(-). Each data point is a mean of three individual measurements and the maximum errors (s.e.) were ± 15%. The errors have been omitted from the graph
for clarity. (B) Cytotoxicity of two selected fusion proteins (H17-BSR and H17-DT-L-BSR-K) in the presence of a specific competing (H17E2) and non-specific
(ASM2) IgG antibody at a concentration of 10 9g ml-' (67 nM). The samples are as follows: H17-BSR (-0-), H17-BSR + 67 nm H17E2 IgG (-0-),
H17-BSR + 67 nm ASM2 IgG (-{-), H17-DT-L-BSR-K (-A-), H17-DT-L-BSR-K + 67 nm H17E2 IgG (-A-), H17-DT-L-BSR-K + 67 nM ASM2 IgG (-U-)
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relative order of toxicity was the same in each case. In fact, the
simple H17-BSR fusion protein was over 1700-fold more toxic to
these cells than bovine seminal ribonuclease, with an IC50 of about
4 nM. The addition ofa C-terminal KDEL sequence made a signifi-
cant difference to the cytotoxicity of the immunotoxin, improving
the IC50 to about 1 nM. Furthermore, the inclusion of a diphtheria
toxin disulphide loop improved the cytotoxicity about threefold to
300 pM. Thus, the most toxic fusion protein is about 2 x 104-fold
more toxic than non-targeted seminal ribonuclease. The inclusion
of a flexible linker between the BSRNase and the scFv did not
seem to affect the cytotoxicity of these immunotoxins. All these
fusion molecules were tested on antigen-negative cells and were
shown not to be cytotoxic over the same concentration ranges
(Table 3).
It was assumed that a small, but insignificant proportion of the
toxicity of the fusion proteins may have been due to the inherent
cytotoxic activity of the BSRNase. This may not be the case if a
dimeric structure was essential for inherent cytotoxicity, as is
postulated (Kim et al, 1995b). To demonstrate that the major mech-
anism of cytotoxicity was due to PLAP targeting, cytotoxicity was
carried out in the presence ofH17E2 IgG. The presence of67 nm of
whole antibody almost completely reversed the directed toxicity of
the fusion proteins. Two of the fusion proteins have been selected
for illustration; these are the extreme differences and all the others
fall in between these results (Figure 4B). The concentration of the
competing antibody used was over 100 times the KD ofthe IgG and,
at this concentration, it was expected that the IgG form would
occupy most of the binding sites on the cell surface. An irrelevant,
non-PLAP-targeting antibody failed to reduce the cytotoxicity of
the fusion proteins, demonstrating that PLAP was the receptor
involved in enzyme delivery and competition.
DISCUSSION
We have described, in this report, the construction, bacterial
expression, refolding, purification and activities of a panel of
single-chain Fv-bovine seminal ribonuclease fusion proteins and
their behaviour in vitro as tumour cell-specific immunotoxins.
Although each partner in these chimaeric molecules is a compact,
well-characterized protein, they are complicated by the presence
of many disulphide bonds (ten per BSRNase dimer and two per
scFv). The six immunotoxins produced here all possess antigen-
binding activity and ribonuclease activity, but it is obvious that
their refolding requirements are different, and a compromise had
to be reached in the conditions applied here to regenerate active
molecules from inclusion bodies.
Bovine seminal ribonuclease has long been known to be an
enzyme with unusual anti-tumour properties. There is much
research on this subject and it is possible that the dimeric structure
of the enzyme endows it with a cryptic cell-binding site, enabling
it to bind and enter tumour cells preferentially over normal cells
(Kim et al, 1995b). We have shown that is possible to over-ride
this inherent binding and provide a more efficient, antigen-specific
cell-targeting function using a single-chain antibody. The incorpo-
ration of a ligand specific for the oncofetal antigen placental alka-
line phosphatase improves cell targeting by over 2 x 104-fold.
Therefore, at the concentrations used, there is insignificant
inherent cell binding.
None of the immunotoxins described here have a translocation
domain, unlike conventional toxin-based immunotoxins. It is
presumed that the target RNA species, whose degradation leads to
cell death, reside in the cytosol. However, the mechanism ofentry
into the cytosol is unclear. It is not disputed that proteins can cross
the cell membrane from an endosome into the cytosol, albeit inef-
ficiently. For example, work by Pastan and his group has shown
that removing domain II (translocation domain) of their TGF-oc-
PE38KDEL immunotoxin still results in an effective molecule,
which is about 10-fold lower in potency (Kihara et al, 1994). Work
by Rybak and co-workers has described a number ofribonuclease-
based immunotoxins targeting the transferrin receptor (Rybak et
al, 1992; Newton et al, 1994). These results indicate that some sort
of receptor-mediated, retrograde transport mechanism is in opera-
tion, of which some of the steps have already been elucidated.
There is one report that BSRNase can destabilize the cell
membrane causing leakage (Mancheno et al, 1994). This could be
a possible mechanism of translocation into the cytosol of this
enzyme. All these observations suggest that the cytotoxicity of
these types of immunotoxins may vary depending on the cell
biology of the receptor targeted.
The differences in potency seen in these six immunotoxins are
not very large, but do fall into three categories. The addition of a
flexible linker between the C-terminus of the scFv and the N-
terminus ofthe ribonuclease makes no difference to the expression,
refolding, quaternary structure, antigen-binding, RNAase activity
or cytotoxicity. This is different to the findings of Rybak and co-
workers, who report that their linker is critical in the function of
their EDN-scFv (Newton et al, 1994). However, as the orientation
oftheir immunotoxin is reversed compared with the ones described
here, these observations may be explained by the fact that the C-
terminus of all these ribonucleases is less exposed than the N-
terminus, which is known to be very flexible in bovine seminal
ribonuclease (Cafaro et al, 1995). The addition of a 'KDEL' endo-
plasmic retention (ER) signal improves the cytotoxicity of these
proteins, perhaps by reducing the amount of fusion protein lost by
protein trafficking and increasing the amount retained in the ER
once it reaches there, by retrograde transport. This could be one of
the points where it crosses the cell membrane to enter the cytosol.
The diphtheria toxin disulphide loop, although small but non-
mammalian in origin, was tested as a possible factor in improving
cytosolic delivery. The theory behind this was that the antigen-
bound scFv could still be associated with the cell membrane,
hindering the release of the ribonuclease into the cytosol. A
reducible bond separating the two moieties may improve this. This
loop did increase effectiveness, but only in combination with the
'KDEL' signal. These results do not rule out the possibility that the
diphtheria toxin peptide may simply be a superior spacer, resulting
in better activity. This work has identified a number of potent
clones, which may behave very differently to each other in vivo, in
terms of activity and pharmacokinetic stability.
The proteins described here were mainly aggregates and
monomers, so it was impossible to determine whether dimeric
binding contributes to increased cytotoxicity. It would be attractive
to increase the amount of dimeric protein obtained (by manipu-
lating the refolding conditions further), as this might be expected to
have advantages over the monomeric ribonuclease immunotoxins
that we tested - they could localize to tumours in vivo more rapidly
and effectively than monomers, because of increased avidity, and
cross-linking ofsurface receptors may also improve internalization.
Work on the native seminal ribonuclease has shown that the
dimeric form is much less sensitive to cytosolic ribonuclease
inhibitor than the monomeric form (Murthy and Sirdeshmukh,
1992) and dimeric BSRNase may also possess a structure that
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causes it to destabilize the lipid bilayer and allow leakage into the
cytosol, acting as a crude translocation function (Mancheno et al,
1994). Therefore these dimeric immunotoxins would possess
properties that would make them far superior molecules.
The fact that dimer formation was a problem in these fusion
protein constructs suggests that linking a scFv to the BSRNase
may interfere with some important determinants of dimerization.
This, most likely, would be the flexible, exchangeable N-termini
and the intersubunit disulphide bridges. Placing a scFv at the N-
terminus may hinder the N-termini swapping process. To support
this, it has recently been shown that it is essential to remove the N-
terminal methionine residue from the translated form of the native
BSRNase protein to form N-terminal-exchanged dimers (Adinolfi
et al, 1995), suggesting that other substitutions, such as a scFv,
may not be tolerated at all in this respect. In addition, incomplete
refolding may not conformationally favour the formation of the
two disulphide bridges. As shown by Kim et al (1995b), preven-
tion ofthe formation ofintersubunit disulphide bridges reduces the
amount of dimers with exchanged N-termini. Previous research
has already shown that refolding of denatured BSRNase by a
method involving a glutathione redox couple results in little dimer
formation (Parente and D'Alessio, 1985). Air oxidation results in
better refolding ofBSRNase, but from our results it is not suitable
for the recombinant antibody. As well as seeing monomers and a
small amount of dimers, we also see higher aggregate forms,
which has also been noted previously.
Fully active dimers of BSRNase (Russo et al, 1993) and single-
chain Fvs (Jost et al, 1994) have been expressed in eukaryotic
systems. There are, therefore, alternative methods for recombinant
protein expression, which may circumvent the refolding step we
find necessary.
In conclusion, we have produced a number of ribonuclease-
based immunotoxins and designed significant alterations that
improve their potency by over tenfold. These molecules are
extremely cytotoxic to PLAP-expressing cancer cells and repre-
sent an improvement of over 2 x 104-fold over native bovine
seminal ribonuclease, which itself is non-toxic to normal cells. We
could speculate that the mode of action of these immunotoxins
involves receptor binding and internalization, followed by an inef-
ficient translation event, either mediated by the BSRNase moiety
itself or by vesicle leakage. The small amount of ribonuclease
enzyme that reaches the target RNA is enough to cause cell death.
As these molecules are monomeric in structure, there is the
promise that even more potent molecules may be generated if a
significant proportion of dimers could be produced. We propose
that the small size and potentially high functional affinity of these
molecules may enable them to penetrate tumours and have a
longer residency there with little or no immunogenicity. RNAase
A (an almost identical monomeric RNAase) has already been used
clinically and has been shown to be tolerated at very high concen-
trations without adverse effects (Glukhov et al, 1976). It is hoped
that these properties will make fusion proteins such as these
important and useful therapeutic molecules.
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